Analysts think CLRB stock price could increase by 717%
Nov 27, 2024, 12:26 PM
-80.33%
What does CLRB do
Cellectar Biosciences, based in Florham Park, New Jersey, develops phospholipid drug conjugates for cancer treatment and imaging, with a focus on targeted therapies and a pipeline including iopofosine. The company went public on May 20, 2005, and employs 20 staff.
6 analysts think CLRB stock price will increase by 717.31%. The current median analyst target is $12.75 compared to a current stock price of $1.56. The lowest analysts target is $7.07 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.